Workflow
Sage Therapeutics(SAGE)
icon
Search documents
Sage Therapeutics(SAGE) - 2021 Q2 - Earnings Call Presentation
2021-08-03 14:37
Investor Presentation August 2021 Safe Harbor Statement • The slides presented today and the accompanying oral presentations contain forward-looking statements, which may be identified by the use of words such as "may," "might," "will," "should," "can,","expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "opportunity", "goal", "mission", "potential," "target", or "continue," and other similar expressions. • Forward-looking statements in this presentation include statements ...
Sage Therapeutics(SAGE) - 2021 Q2 - Quarterly Report
2021-08-03 11:20
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36544 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR Sage Therapeutics, Inc. (Exact name of registrant as specified in its Charter) (State or other jurisdiction of incorporati ...
Sage Therapeutics(SAGE) - 2021 Q1 - Earnings Call Transcript
2021-05-04 18:18
SAGE Therapeutics, Inc. (NASDAQ:SAGE) Q1 2021 Earnings Conference Call May 4, 2021 8:00 AM ET Company Participants Jeff Boyle - Investor Contact Barry Greene - President, CEO & Director Stephen Kanes - Chief Medical Officer Kimi Iguchi - CFO & Treasurer Jim Doherty - Chief Research Officer Conference Call Participants Andrew Tsai - Jefferies Ritu Baral - Cowen and Company Tazeen Ahmad - Bank of America Merrill Lynch Yasmeen Rahimi - Piper Sandler & Co. Turner Kufe - JPMorgan Chase & Co. Laura Chico - Wedbus ...
Sage Therapeutics(SAGE) - 2021 Q1 - Earnings Call Presentation
2021-05-04 15:20
Investor Presentation May 2021 Safe Harbor Statement • The slides presented today and the accompanying oral presentations contain forward-looking statements, which may be identified by the use of words such as "may," "might," "will," "should," "can,","expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "opportunity", "goal", "mission", "potential," "target", or "continue," and other similar expressions. • Forward-looking statements in this presentation include statements reg ...
Sage Therapeutics(SAGE) - 2021 Q1 - Quarterly Report
2021-05-04 11:20
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36544 Sage Therapeutics, Inc. (Exact name of registrant as specified in its Charter) (State or other jurisdiction of incorporat ...
Sage Therapeutics(SAGE) - 2020 Q4 - Earnings Call Transcript
2021-02-24 19:23
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2020 Earnings Conference Call February 8, 2021 8:00 AM ET Company Participants Barry Greene - CEO Jeff Boyle - Head-Investor Relations Mike Cloonan - Chief Operating Officer Kimi Iguchi - Chief Financial Officer Steve Kanes - Chief Medical Officer Conference Call Participants Laura Chico - Wedbush Securities Andrew Tsai - Jefferies Paul Matteis - Stifel Yatin Suneja - Guggenheim Partners Jay Olson - Oppenheimer Salveen Richter - Goldman Sachs Tazeen Ahmad - Bank of ...
Sage Therapeutics(SAGE) - 2020 Q4 - Earnings Call Presentation
2021-02-24 13:17
Investor Presentation February 2021 Safe Harbor Statement • The slides presented today and the accompanying oral presentations contain forward-looking statements, which may be identified by the use of words such as "may," "might," "will," "should," "can,","expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "opportunity", "goal", "mission", "potential," or "continue," and other similar expressions. • Forward-looking statements in this presentation include statements regardin ...
Sage Therapeutics(SAGE) - 2020 Q4 - Annual Report
2021-02-24 12:15
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR For the transition period from to Commission file number: 001-36544 Sage Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation o ...
Sage Therapeutics (SAGE) Presents At 39th Annual J.P. Morgan Healthcare Conference
2021-01-20 23:05
J.P. Morgan Healthcare Conference January 2021 Safe Harbor Statement • The slides presented today and the accompanying oral presentations contain forward-looking statements, which may be identified by the use of words such as "may," "might," "will," "should," "can,","expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "opportunity", "goal", "mission", "potential," or "continue," and other similar expressions. • Forward-looking statements in this presentation include statemen ...
Sage Therapeutics(SAGE) - 2020 Q3 - Earnings Call Presentation
2020-11-08 19:33
Investor Presentation November 2020 Safe Harbor Statement • The slides presented today and the accompanying oral presentations contain forward-looking statements, which may be identified by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "opportunity", "goal", "potential," or "continue," and other similar expressions. Forward-looking statements in this presentation include statements regarding: our views and exp ...